Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Depression 4Depressive Disorder, Major 2Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Neoplasms 1Lymphoma, Follicular 1Lung Neoplasms 1Liver Neoplasms 1Head and Neck Neoplasms 1Gallbladder Neoplasms 1Fatigue 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Bile Duct Neoplasms 1Asthma 1

Interventions

Gemcitabine 57Paclitaxel 50Cyclophosphamide 45pembrolizumab 44Carboplatin 41Bevacizumab 38Cisplatin 33Docetaxel 31Fluorouracil 30Nivolumab 29Capecitabine 29Pemetrexed 24Irinotecan 24Oxaliplatin 23Dexamethasone 23Ipilimumab 22Leucovorin 21Radiotherapy 20Sorafenib 19Doxorubicin 19Everolimus 18Cetuximab 18fludarabine 17Albumin-Bound Paclitaxel 17trametinib 15Sunitinib 15Rituximab 15Erlotinib Hydrochloride 15130-nm albumin-bound paclitaxel 15Prednisone 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasms × Escitalopram × Clear all
NCT00352885 2018-09-14

Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment

Emory University

Phase 4 Completed
20 enrolled 11 charts

Depression, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡